Summary
62 / 100 · Bulios Score
What speaks for it
- Out of every 100 INR of revenue, 21 INR is left as net profit.
- It holds more cash than debt: ₹1.12B against ₹789.2M.
- It earns 11 INR a year on every 100 INR of invested capital.
- Earnings per share grew by 7.8% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue growth is slowing: 0.3% a year over the last 3 years against 11% over 5 years.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 93.7 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (INR)
Diluted EPS (INR)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 0.3% a year. Earnings per share grew by 7.8% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 INR of revenue goes
- Cost of sales 44 INR
- Sales and administration 31 INR
- Taxes and other 4.7 INR
- Net profit 21 INR
Net profit, industry median (Chemicals - Specialty) 6.1 INR
Out of every 100 INR of revenue, 21 INR is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.5 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.20%
- Paid out of profit
- 19%
You receive 12.00 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail